sTREM2 as Biomarker of Cystatin-C Therapeutic Efficacy

Target: ? Composite Score: 0.708 Price: $0.71▲11.8% Citation Quality: Pending neurodegeneration Status: proposed

☰ Compare ⚔ Duel ⚛ Collideinteract with this hypothesis

⚠ No Target Gene⚠ Low Validation Senate Quality Gates →

Quality Report Card click to collapse

B+

Composite: 0.708

Top 7% of 660 hypotheses

T5 Contested

Contradicted by evidence, under dispute

B+ Mech. Plausibility 15% 0.72 Top 48%

C+ Evidence Strength 15% 0.58 Top 61%

B Novelty 12% 0.65 Top 81%

B+ Feasibility 12% 0.75 Top 34%

B Impact 12% 0.68 Top 65%

A Druggability 10% 0.80 Top 31%

B+ Safety Profile 8% 0.70 Top 30%

C+ Competition 6% 0.55 Top 78%

B+ Data Availability 5% 0.72 Top 38%

B Reproducibility 5% 0.68 Top 42%

Evidence

3 supporting | 3 opposing

Citation quality: 0%

Debates

0 sessions

No debates yet

Convergence

0.00 F 30 related hypothesis share this target

Hypotheses from Same Analysis (4)

These hypotheses emerged from the same multi-agent debate that produced this hypothesis.

Complement Cascade Inhibition Synaptic Protection

Score: 0.670 | Target: ?

Microglial Senescence Prevention via TREM2/SASP Axis

Score: 0.664 | Target: ?

Gamma Oscillation Enhancement Synergy

Score: 0.638 | Target: ?

Lysosomal Cathepsin-Dependent Tau Clearance

Score: 0.567 | Target: ?

Description

CSF sTREM2 levels serve as pharmacodynamic biomarker for cystatin-C-mediated tau and neuroinflammation modulation. Baseline sTREM2/cystatin-C ratios predict therapeutic response across tau, inflammation, and synaptic biomarkers.

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.

6 citations 6 with PMID Validation: 0% 3 supporting / 3 opposing

✓ For (3)

No supporting evidence

No opposing evidence

(3) Against ✗

High Medium Low

Evidence Matrix — sortable by strength/year, click Abstract to expand

Evidence Types

MECH 1CLIN 2GENE 3EPID 0

Claim	Stance	Category	Source	Strength ↕	Year ↕	Quality ↕	PMIDs	Abstract
sTREM2 in CSF provides insights into microglial ac…	Supporting	CLIN	-	-	-	-	PMID:38172904	-
TREM2 R47H mutation abrogates cystatin-C effects o…	Supporting	GENE	-	-	-	-	PMID:41576952	-
Cystatin-C and TREM2 co-localize in microglia in b…	Supporting	MECH	-	-	-	-	PMID:41576952	-
sTREM2 levels are influenced by multiple factors (…	Opposing	GENE	-	-	-	-	PMID:38172904	-
If TREM2 mutations block cystatin-C function, sTRE…	Opposing	GENE	-	-	-	-	PMID:41576952	-
Biomarker ≠ mechanism; even if sTREM2 predicts res…	Opposing	CLIN	-	-	-	-	PMID:38172904	-

Legacy Card View — expandable citation cards

✓ Supporting Evidence 3

sTREM2 in CSF provides insights into microglial activation states and AD progression

PMID:38172904

TREM2 R47H mutation abrogates cystatin-C effects on amyloid clearance, establishing TREM2 dependency

PMID:41576952

Cystatin-C and TREM2 co-localize in microglia in brain parenchyma

PMID:41576952

✗ Opposing Evidence 3

sTREM2 levels are influenced by multiple factors (APOE genotype, disease stage, other genetic variants), poten…▼

sTREM2 levels are influenced by multiple factors (APOE genotype, disease stage, other genetic variants), potentially confounding CST3-specific signal

PMID:38172904

If TREM2 mutations block cystatin-C function, sTREM2 may not reflect CST3 efficacy—only TREM2 integrity

PMID:41576952

Biomarker ≠ mechanism; even if sTREM2 predicts response, this does not validate any therapeutic mechanism

PMID:38172904

Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.

No linked debates yet. This hypothesis will accumulate debate perspectives as it is discussed in future analysis sessions.

Price History

7d Trend

↗

Rising

7d Momentum

▲ 11.8%

Volatility

High

0.0606

Events (7d)

⚡ Price Movement Log Recent 6 events

	Event	Price	Change	Source	Time
💬	Debate Round	$0.682	▲ 7.5%	market_dynamics	2026-04-17 13:58
📄	New Evidence	$0.635		market_dynamics	2026-04-17 08:36
📊	Score Update	$0.635	▲ 4.1%	market_dynamics	2026-04-17 07:12
📄	New Evidence	$0.610	▼ 8.0%	evidence_update	2026-04-17 01:58
📄	New Evidence	$0.663	▲ 8.7%	evidence_update	2026-04-17 01:58
✨	Listed	$0.610		post_process	2026-04-17 01:58